Prof Anthony Moorman speaks to ecancer in an online interview for the virtual EHA 2020 meeting.
He explains the background and design of the trial, which aims to assess the efficacy of using a tyrosine kinase inhibitor, imatinib, to treat patients with acute lymphoblastic leukaemia (ALL) and an ABL-class fusion.
Prof Moorman details the results from this study - in which improved clinical outcomes were seen with this intervention.
He also outlines the next steps for this study, which includes the launch of the ALLTogether 01 trial.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.